Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells

Kleebsabai Srivannaboon, Armen B. Shanafelt, Elisabetta Todisco, Carla P. Forte, Frederick G. Behm, Susana C. Raimondi, Ching Hon Pui, Dario Campana

Research output: Contribution to journalArticle

Abstract

Interleukin 4 (IL-4) suppresses the growth of acute lymphoblastic leukemia (ALL) cells, but its clinical usefulness is limited by proinflammatory activity due mainly to the interaction of cytokine with endothelial cells and fibroblasts. Stroma-supported cultures of leukemic lymphoblasts were used to test the antileukemic activity of an IL-4 variant, BAY 36-1677, in which the mutations Arg 121 to Glu and Thr 13 to Asp ensure high affinity for IL-4Rα/IL-2Rγ receptors expressed by lymphoid cells, without activation of the IL-4Rα/IL-13Rα receptors mainly expressed by other cells. BAY 36-1677 (25 ng/mL) was cytotoxic in 14 of 16 cases of B-lineage ALL; the median reduction in cell recovery after 7 days of culture was 85% (range, 17%-95%) compared to results of parallel cultures not exposed to the cytokine. Twelve of the 14 sensitive cases had t(9;22) or 11q23 abnormalities; 3 were obtained at relapse. BAY 36-1677 induced apoptosis in leukemic lymphoblasts but did not substantially affect the growth of normal CD34+ cells, thus conferring a growth advantage to normal hematopoietic cells over leukemic lymphoblasts in vitro. BAY 36-1677 had antileukemic activity equal or superior to that produced by native IL-4, but it lacked any effects on the growth of endothelial cells and fibroblasts. The molecular manipulation of IL-4 to abrogate its proinflammatory activity has generated a novel and therapeutically promising cytokine for the treatment of high-risk ALL.

Original languageEnglish
Pages (from-to)752-758
Number of pages7
JournalBlood
Volume97
Issue number3
DOIs
Publication statusPublished - Feb 1 2001

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interleukin-4
Apoptosis
Endothelial cells
Fibroblasts
Cytokines
Growth
Endothelial Cells
Cell culture
Chemical activation
Recovery
interleukin-4 variant
Lymphocytes
Recurrence
Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Srivannaboon, K., Shanafelt, A. B., Todisco, E., Forte, C. P., Behm, F. G., Raimondi, S. C., ... Campana, D. (2001). Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. Blood, 97(3), 752-758. https://doi.org/10.1182/blood.V97.3.752

Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. / Srivannaboon, Kleebsabai; Shanafelt, Armen B.; Todisco, Elisabetta; Forte, Carla P.; Behm, Frederick G.; Raimondi, Susana C.; Pui, Ching Hon; Campana, Dario.

In: Blood, Vol. 97, No. 3, 01.02.2001, p. 752-758.

Research output: Contribution to journalArticle

Srivannaboon, K, Shanafelt, AB, Todisco, E, Forte, CP, Behm, FG, Raimondi, SC, Pui, CH & Campana, D 2001, 'Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells', Blood, vol. 97, no. 3, pp. 752-758. https://doi.org/10.1182/blood.V97.3.752
Srivannaboon, Kleebsabai ; Shanafelt, Armen B. ; Todisco, Elisabetta ; Forte, Carla P. ; Behm, Frederick G. ; Raimondi, Susana C. ; Pui, Ching Hon ; Campana, Dario. / Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells. In: Blood. 2001 ; Vol. 97, No. 3. pp. 752-758.
@article{5f52133c66754d0e842c00990ad8ae04,
title = "Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells",
abstract = "Interleukin 4 (IL-4) suppresses the growth of acute lymphoblastic leukemia (ALL) cells, but its clinical usefulness is limited by proinflammatory activity due mainly to the interaction of cytokine with endothelial cells and fibroblasts. Stroma-supported cultures of leukemic lymphoblasts were used to test the antileukemic activity of an IL-4 variant, BAY 36-1677, in which the mutations Arg 121 to Glu and Thr 13 to Asp ensure high affinity for IL-4Rα/IL-2Rγ receptors expressed by lymphoid cells, without activation of the IL-4Rα/IL-13Rα receptors mainly expressed by other cells. BAY 36-1677 (25 ng/mL) was cytotoxic in 14 of 16 cases of B-lineage ALL; the median reduction in cell recovery after 7 days of culture was 85{\%} (range, 17{\%}-95{\%}) compared to results of parallel cultures not exposed to the cytokine. Twelve of the 14 sensitive cases had t(9;22) or 11q23 abnormalities; 3 were obtained at relapse. BAY 36-1677 induced apoptosis in leukemic lymphoblasts but did not substantially affect the growth of normal CD34+ cells, thus conferring a growth advantage to normal hematopoietic cells over leukemic lymphoblasts in vitro. BAY 36-1677 had antileukemic activity equal or superior to that produced by native IL-4, but it lacked any effects on the growth of endothelial cells and fibroblasts. The molecular manipulation of IL-4 to abrogate its proinflammatory activity has generated a novel and therapeutically promising cytokine for the treatment of high-risk ALL.",
author = "Kleebsabai Srivannaboon and Shanafelt, {Armen B.} and Elisabetta Todisco and Forte, {Carla P.} and Behm, {Frederick G.} and Raimondi, {Susana C.} and Pui, {Ching Hon} and Dario Campana",
year = "2001",
month = "2",
day = "1",
doi = "10.1182/blood.V97.3.752",
language = "English",
volume = "97",
pages = "752--758",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells

AU - Srivannaboon, Kleebsabai

AU - Shanafelt, Armen B.

AU - Todisco, Elisabetta

AU - Forte, Carla P.

AU - Behm, Frederick G.

AU - Raimondi, Susana C.

AU - Pui, Ching Hon

AU - Campana, Dario

PY - 2001/2/1

Y1 - 2001/2/1

N2 - Interleukin 4 (IL-4) suppresses the growth of acute lymphoblastic leukemia (ALL) cells, but its clinical usefulness is limited by proinflammatory activity due mainly to the interaction of cytokine with endothelial cells and fibroblasts. Stroma-supported cultures of leukemic lymphoblasts were used to test the antileukemic activity of an IL-4 variant, BAY 36-1677, in which the mutations Arg 121 to Glu and Thr 13 to Asp ensure high affinity for IL-4Rα/IL-2Rγ receptors expressed by lymphoid cells, without activation of the IL-4Rα/IL-13Rα receptors mainly expressed by other cells. BAY 36-1677 (25 ng/mL) was cytotoxic in 14 of 16 cases of B-lineage ALL; the median reduction in cell recovery after 7 days of culture was 85% (range, 17%-95%) compared to results of parallel cultures not exposed to the cytokine. Twelve of the 14 sensitive cases had t(9;22) or 11q23 abnormalities; 3 were obtained at relapse. BAY 36-1677 induced apoptosis in leukemic lymphoblasts but did not substantially affect the growth of normal CD34+ cells, thus conferring a growth advantage to normal hematopoietic cells over leukemic lymphoblasts in vitro. BAY 36-1677 had antileukemic activity equal or superior to that produced by native IL-4, but it lacked any effects on the growth of endothelial cells and fibroblasts. The molecular manipulation of IL-4 to abrogate its proinflammatory activity has generated a novel and therapeutically promising cytokine for the treatment of high-risk ALL.

AB - Interleukin 4 (IL-4) suppresses the growth of acute lymphoblastic leukemia (ALL) cells, but its clinical usefulness is limited by proinflammatory activity due mainly to the interaction of cytokine with endothelial cells and fibroblasts. Stroma-supported cultures of leukemic lymphoblasts were used to test the antileukemic activity of an IL-4 variant, BAY 36-1677, in which the mutations Arg 121 to Glu and Thr 13 to Asp ensure high affinity for IL-4Rα/IL-2Rγ receptors expressed by lymphoid cells, without activation of the IL-4Rα/IL-13Rα receptors mainly expressed by other cells. BAY 36-1677 (25 ng/mL) was cytotoxic in 14 of 16 cases of B-lineage ALL; the median reduction in cell recovery after 7 days of culture was 85% (range, 17%-95%) compared to results of parallel cultures not exposed to the cytokine. Twelve of the 14 sensitive cases had t(9;22) or 11q23 abnormalities; 3 were obtained at relapse. BAY 36-1677 induced apoptosis in leukemic lymphoblasts but did not substantially affect the growth of normal CD34+ cells, thus conferring a growth advantage to normal hematopoietic cells over leukemic lymphoblasts in vitro. BAY 36-1677 had antileukemic activity equal or superior to that produced by native IL-4, but it lacked any effects on the growth of endothelial cells and fibroblasts. The molecular manipulation of IL-4 to abrogate its proinflammatory activity has generated a novel and therapeutically promising cytokine for the treatment of high-risk ALL.

UR - http://www.scopus.com/inward/record.url?scp=0035253868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035253868&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.3.752

DO - 10.1182/blood.V97.3.752

M3 - Article

C2 - 11157494

AN - SCOPUS:0035253868

VL - 97

SP - 752

EP - 758

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -